Add BrightSurf on Google Email

UMass Amherst researchers combine bacteria and viruses to demonstrate a new way to fight cancer

Researchers at UMass Amherst have designed a new therapy that combines engineered Salmonella bacteria with oncolytic viruses to target liver and pancreatic cancer. The treatment showed promising results in animal models, leading to significant tumor reduction and improved survival rates.

SourceUniversity of Massachusetts Amherst·JournalCell Reports Medicine·TypeRandomized controlled/clinical trial·DateJun 3, 2026

AI enables the design of new molecules that selectively target specific cells

Researchers at IRB Barcelona used AI to design new chemical entities that selectively target specific cell types, demonstrating superior activity compared to conventional screening strategies. The methodology, called phenotypic discovery, uses observable responses in cells rather than a specific molecular target.

SourceInstitute for Research in Biomedicine (IRB Barcelona)·JournalCommunications Chemistry·DateJun 2, 2026

New global analysis confirms alcohol’s complex relationship with health: clear cancer risks and chronic liver diseases at any level, mixed evidence for other cardiometabolic conditions

The study found high-risk associations between alcohol use and all ten cancers examined, with risk increasing progressively as intake rose. Low-to-moderate drinking was associated with lower disease risk for type 2 diabetes, Alzheimer's disease, ischemic heart disease, and stroke.

Recent advances in the diagnosis and treatment of fat accumulation in liver and pancreas

Researchers highlight latest developments in pathology, diagnosis, and treatment of MASLD and IPFD, revealing correlations with chronic diseases like liver cancer and pancreatic cancer. Innovative treatments, such as AI-driven approaches and organ-targeted therapies, show promise for precision prevention and therapy.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalPortal Hypertension & Cirrhosis·TypeSystematic review·DateJun 1, 2026

RAS(ON) inhibitor doubles median overall survival in results of phase 3 trial for patients with metastatic pancreatic cancer

A phase 3 trial shows daraxonrasib, an oral RAS(ON) multi-selective inhibitor, improves overall and progression-free survival compared to chemotherapy in patients with metastatic pancreatic cancer. The treatment also demonstrated substantial tumor shrinkage or disappearance in patients with a known RAS G12 mutation.

SourceDana-Farber Cancer Institute·JournalNew England Journal of Medicine·DateMay 31, 2026

Study sheds light on how early pancreas lesions become cancerous

Researchers have discovered that precursor lesions in the pancreas, often considered a step towards cancer, do not undergo malignant transformation if they lack a specific microenvironment. The team used advanced technologies to isolate and analyze single cells from over 150 donated pancreases, finding that the microenvironment surroun...

SourceMichigan Medicine - University of Michigan·JournalCancer Discovery·TypeExperimental study·DateMay 21, 2026

New study aids earlier diagnosis of pancreatic cancer in patients with low-risk pancreatic cysts

A new study published in JAMA Network Open found that patients with low-risk pancreatic cystic lesions have a high risk of developing pancreatic cancer. The study highlights the need for long-term personalized surveillance strategies for these patients, which could enable earlier detection and treatment of the disease.

SourceMass General Brigham·JournalJAMA Network Open·TypeObservational study·DateMay 20, 2026

New targeted radiopharmaceutical therapy induces remission in pancreatic cancer model

Researchers have developed a targeted radiopharmaceutical treatment that can effectively slow tumor growth in pancreatic ductal adenocarcinoma, achieving complete remission in preclinical models. The treatment targets CD44v6 expression and has shown promise as a new option for patients with this highly aggressive cancer.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateMay 15, 2026

RAS(ON) inhibitor daraxonrasib shows promising results in advanced pancreatic cancer phase 1/2 study

A phase 1/2 trial of daraxonrasib, a RAS(ON) multi-selective inhibitor, demonstrated safety and broad activity against RAS-mutant metastatic pancreatic cancer. The drug showed promising signs of activity, with approximately 30% of patients experiencing an objective response and 90% experiencing disease control.

SourceDana-Farber Cancer Institute·JournalNew England Journal of Medicine·DateMay 6, 2026

RAS inhibitor daraxonrasib demonstrates initial anti-tumor activity in pancreatic cancer

The Phase 1/2 trial demonstrated a 29% response rate and median overall survival of 15.6 months, outperforming historical chemotherapy response rates. Daraxonrasib targets RAS in its 'on' state and has shown durable responses with a manageable safety profile.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMay 6, 2026

Trinity researchers publish ‘playbook’ for understanding pancreatic cancer, one of the deadliest cancers

Researchers at Trinity College Dublin have published a comprehensive review of pancreatic cancer, explaining why it's resistant to treatment and where new hope may emerge. The study identifies multiple biological systems interacting to drive the disease's growth and suggests combination-based treatments targeting multiple hallmarks of ...

SourceTrinity College Dublin·JournalCancer Letters·TypeNews article·DateMay 6, 2026

New scoring tool shows radiation can reprogram pancreatic tumor environment

A new composite scoring system, HOST-Factor, quantifies the functional state of the tumor microenvironment in pancreatic cancer. The study demonstrates the effectiveness of pulsed low-dose-rate chemoradiation in shifting the tumor microenvironment from a tumor-promoting to a tumor-restricting state.

SourceTemple University Health System·JournalGastro Hep Advances·TypeRandomized controlled/clinical trial·DateApr 23, 2026

From benign growth to pancreatic cancer: New study shows how the switch gets flipped

A recent study published in Cell reveals the molecular mechanisms underlying the transformation of benign pancreatic cells into malignant tumors. Researchers identified a subset of precancerous cells that closely resemble tumor cells, characterized by high oncogenic drive and strongly activated tumor-suppressors. This discovery offers ...

AACR: Targeted drug delivery for colorectal cancer, COVID-19’s impact on breast cancer outcomes, AI in cancer diagnosis and more

UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.

Targeting tumor supporting cells: Advancing CAR T success in pancreatic cancer

Researchers have developed a new CAR T therapy that targets tumor-supporting cells in pancreatic cancer, paving the way for a potentially safer and more effective treatment. The therapy uses lipid nanoparticles to deliver CAR instructions directly to patient T cells, resulting in higher expression rates and improved efficacy compared t...

SourceUniversity of Pennsylvania·JournalCancer Immunology Research·TypeExperimental study·DateMar 31, 2026

ESE and ESPE launch joint transition of care guidance to improve outcomes for young people moving from child to adult endocrine care

The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.

Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer

A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.

Sensing local fibers in pancreatic tumors, cancer cells ‘choose’ to either grow or tolerate treatment

A new study shows that pancreatic cancer cells' ability to detect the extracellular matrix determines their growth rate and response to chemotherapy. The researchers found that cells detecting ECM have low autophagy levels and high growth rates, while those farther away from ECM have high autophagy levels and can survive chemotherapy.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalCell·TypeExperimental study·DateFeb 16, 2026

Cancer Cell publication details development of cancer-induced cachexia and anorexia

Cancer cell researchers at the University of Oklahoma have developed a novel 'triangle regulation theory' that explains the development of cancer-induced cachexia and anorexia. The theory reveals how cancer cells recruit immune cells to trigger excess production of growth factor 15, leading to muscle wasting and loss of appetite.

SourceUniversity of Oklahoma·JournalCancer Cell·TypeExperimental study·DateFeb 12, 2026

Mayo Clinic study finds chemotherapy before surgery improves survival in early-stage pancreatic cancer

Researchers found that when pancreatic tumors touch the superior mesenteric vein, patients who undergo surgery first experience reduced survival rates. In contrast, those who receive chemotherapy before surgery have similar survival outcomes to those with non-vein touching tumors. The study suggests reclassifying tumors based on vein i...

SourceMayo Clinic·JournalJournal of the National Comprehensive Cancer Network·DateFeb 9, 2026

Let’s get on pancreatic cancer’s nerves

Scientists found that tumor-promoting fibroblasts attract nerve fibers through a vicious cycle of signaling and neurotransmitter release. This cycle promotes pre-cancerous growth and pulls in more nerve fibers, leading to a self-reinforcing loop. Disrupting this cycle may lead to new therapies for pancreatic cancer.

SourceCold Spring Harbor Laboratory·JournalCancer Discovery·DateFeb 9, 2026

A CNIO study completely eliminates pancreatic tumors in mice without resistance developing

A study published in PNAS successfully eliminated pancreatic tumours in mice completely and durably, with no significant side effects. The treatment, combining three molecular targets, induced robust regression of experimental PDACs without causing tumor resistance.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateFeb 3, 2026